Survival rates for blood cancers – including lymphoma, myeloma and some types of leukemia – have dramatically increased over the past decade, due in great part to novel treatment approaches including molecularly-targeted therapies and immunotherapies.
In contrast to traditional forms of treatment which were largely episodic and finite (ie, a set number of cycles of intravenous chemotherapy), therapy for some hematological cancers may now be given continuously over years, or in some cases indefinitely.
However, a new Commission by The Lancet Haematology shows how current methods of reporting adverse events, focused on assessing a drug or regimen’s safety, often fail to also appropriately identify importantly delayed, chronic or cumulative effects that can affect patients substantially.
In particular, the toxicity over time and tolerability to the patient of new chronic or continuously administered therapies are not well defined and are poorly captured by existing reporting mechanisms.
The Commission brings together 40 leading clinicians, clinical investigators, regulators, biostatisticians and patient advocates to analyze the evidence and propose recommendations to policymakers, researchers, industry and regulators, and will be launched at the European Haematological Association meeting in Stockholm.
“The success in outcomes and survival in many hematological malignancies is historically unparalleled and fuelled by scientific discovery and implementation. Patients are now living with the challenge of managing not just their hematological malignancy, but also managing chronic therapy for their illness, with new types of acute, chronic, cumulative and late toxicities. Measures to address the broad facets of toxicity assessment must be prioritized and further developed to ultimately enhance accurate, comprehensive, patient-centered toxicity reporting that will meaningfully inform the care of patients with blood cancers,” says Commission Chair Dr. Gita Thanarajasingam, Mayo Clinic, Rochester (MN), USA.
The authors propose new approaches to evaluating and reporting adverse events to complement the current methods. These include expanding reporting beyond high grade, acute toxic side-effects, and capturing less severe but chronic side effects, and cumulative and late effects in a more standardized manner. While short term side effects with some regimens might include nausea and vomiting occurring over a few days in a cycle, long term effects might include neuropathy which worsens over time with ongoing drug exposure and can persist even after therapy is complete, for example.
Additionally, the authors emphasize that changes to the clinical trial design to accommodate delayed adverse events, and incorporating patient-reported outcomes into trials to assess and improve tolerability, adherence and quality of life are essential.
The Commission also examines streamlined approaches to identify unexpected side effects from stem cell transplantation and improved evaluation of late and long-term side effects in survivors. As newer treatments in hematological malignancies are offered more widely, capturing data from population studies will be essential to understanding side effects outside of clinical trial settings. Additionally, post-marketing surveillance by regulatory agencies should adapt to include relevant data on long-term adverse events in a real-world patient population.
